Ad comm review today for Durata and Cubist

The Anti-Infective Drugs Advisory Committee reviews Durata Therapeutics' (DRTX) dalbavancin and Cubist Pharmaceuticals' (CBST) tedizolid today.

The FDA granted both products priority review status under the less-rigorous "non-inferiority" method.

Dalbavancin is comparable to vancomycin, but it is administered via two IV infusions a week apart and enables the patient to avoid two weeks of hospitalization.

Tedizolid is also comparable to an existing drug but it will be evaluated for hospital-acquired MRSA infections.

Two other antibiotics given the accelerated review have a heightened risk of serious adverse events and/or death.


Comments (1)
  • Patent News
    , contributor
    Comments (1475) | Send Message
    both halted?
    31 Mar 2014, 07:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs